We estimate that people who are homozygous for the risk alleles at both the GLP1R and GIPR loci have a 14.8-fold increased odds (95% confidence interval [6.2, 35.8]) of tirzepatide-mediated vomiting, compared with those homozygous for the non-risk alleles
MMP-9, matrix metalloproteinase 9
The SHAPE study, analyzing real-world prescribing data, found: At 3 months: tirzepatide users lost 5.9% of body weight versus 3.6% for semaglutide At 6 months: 10.1% versus 5.8% At 12 months: 15.3% versus 8.3% These are averages from actual patients, not trial participants
23 Retrospective cohort studies indicate that T2DM significantly increases the risk of cardiovascular events, malignant tumors, and liver-related outcomes in MASLD patients
Injectables and dermal fillers such as Botox, lasers, and a quality skincare routine will all help to get rid of and prevent crows feet
Our Peptide Lab reconstitution calculator can help avoid concentration errors